Monthly Archives: September 2023

2023 ACC Research Award Winner

This year’s award is made possible once again thanks to the Elliot Dallen Charitable Trust and their 3-year commitment of £10,000 per year for research into ACC. It was certainly encouraging to receive 3 excellent applications from UK researchers this year which made the judge’s jobs a challenge when selecting just one. However, we are pleased to report that the 2023 ACC Research Award has been awarded to Dr James MacFarlane and team at Cambridge University Hospitals NHS Foundation Trust for their project entitled, ‘Exploring Continue reading →


November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND (and therefore ACCSUK) is a member representing genetic neuroendocrine tumour syndromes.  To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00. On Thursday 9th November, 2023, Professor Karim Meeran from Imperial in London, will give an overview of the relevance of NET Cancer Day to Continue reading →

ADIUVO Clinical Trial Publishes Results Article

On August 21, the final results of the ADIUVO trial were published online in The Lancet Diabetes & Endocrinology. ADIUVO is the first randomized trial to assess the efficacy and safety of adjuvant mitotane treatment in patients with completely resected adrenocortical carcinoma (ACC). The ADIUVO trial was an independent, investigator-initiated study supported by public funding and endorsed by the European Network for the Study of Adrenal Tumours (ENSAT). The study was the result of a tremendous effort of the ENSAT community. Despite limited funding, the Continue reading →